All In Biotech

Drug Trial Radar · NCT05676931

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 21, 2023

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Arcus Biosciences, Inc.
First posted
Jan 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

Conditions

  • Advanced Non-Small Cell Lung Cancer

Interventions

  • DomvanalimabDrug

    Administered as specified in the treatment arm

  • QuemliclustatDrug

    Administered as specified in the treatment arm

  • ZimberelimabDrug

    Administered as specified in the treatment arm

  • DocetaxelDrug

    Administered as specified in the treatment arm

  • Platinum-Based DoubletDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: Up to 58 months
  2. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 58 months

Locations

53 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB)

    Birmingham, Alabama

  • University of California San Diego (UCSD)

    La Jolla, California

  • Memorial Cancer Institute at Memorial Regional Hospital

    Hollywood, Florida

  • Hematology Oncology Associates Of The Treasure Coast

    Port Saint Lucie, Florida

  • Florida Cancer Specialists (Administration and Drug Shipment)

    The Villages, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Ochsner Clinic Foundation

    Jefferson, Louisiana

  • Henry Ford Hospital

    Detroit, Michigan

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Medical Oncology Associated, PS (dba Summit Cancer Centers)

    Spokane, Washington

  • The Border Cancer Hospital

    Albury, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • Cancer Research SA Pty Ltd

    Adelaide, South Australia, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque

    Bordeaux, France

  • Hospices Civils de Lyon Centre Hospitalier Lyon Sud

    Lyon, France

  • Institut De Cancerologie Strasbourg Europe ICANS

    Strasboug, France

  • Hopital FOCH

    Suresnes, France

  • LTD High Technology Hospital Medcenter

    Batumi, Georgia

  • Caucasus Medical Center

    Tbilisi, Georgia

  • Israel Georgian Medical Research Clinic Healthycore

    Tbilisi, Georgia

  • JSC K. Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • Ltd Pineo Medical Ecosystem

    Tbilisi, Georgia

  • Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST

    Meldola, Italy

  • stituto Nazionale per lo Studio e la Cura dei Tumori

    Milan, Italy

  • Istituto Oncologico Veneto IRCCS

    Padova, Italy

  • Azienda Sanitaria Territoriale Pesaro Urbino (AST PU)

    Pesaro, Italy

  • Fondazione IRCCS Istituto Nazionale dei tumori di Milano

    Rome, Italy

  • Szpitale Pomorskie sp. z o.o

    Gdynia, Poland

  • Uniwersyteckie Centrum Kliniczne, im. prof. K. Gibińskiego

    Katowice, Poland

  • Medpolonia Sp. Z.o.o.

    Poznan, Poland

  • Centrum Onkologii - Instytut im. Marii Sk?odowskiej-Curie

    Warsaw, Poland

  • Samsung Changwon Hospital

    Changwon-Si, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

  • Chonam National University Hwasun Hospital

    Hwasun-gun, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitari Mutua Terrassa

    Barcelona, Spain

  • UOMI Cancer Centre

    Barcelona, Spain

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.